Is Regeneron Stock Heading to $590?
Shares of Regeneron (NASDAQ: REGN), which were trading below $500 ahead of the biggest healthcare investors conference of the year, have been on the rise following the company's recent presentation. Wall Street analysts have upgraded the stock, and Benchmark analyst Aydin Huseynov raised his price target to $590 per share.
On Tuesday, the U.S. government agreed to buy another 1.25 million doses of Regeneron's antiviral treatment for COVID-19. But the deal, worth up to $2.6 billion, isn't the biggest reason Wall Street is bullish on Regeneron.
Image source: Getty Images.
Source Fool.com
